A High proliferative index of recurrent melanoma is associated with worse survival

Oncology

Volumn 80, Issue 3-4, 2011, Pages 181-187

  Tu, Ting J ^a,b   Ma, Michelle W ^a,b   Monni, Stefano ^d   Rose, Amy E ^a,b   Yee, Herman ^a,b   Darvishian, Farbod ^a,b   Polsky, David ^a,b   Berman, Russell S ^a,b   Shapiro, Richard L ^a,b   Pavlick, Anna C ^a,b,c   Mazumdar, Madhu ^d   Osman, Iman ^a,b,c  

^a NEW YORK UNIVERSITY   (United States)

^b Department of Dermatology ^*  (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Disease free survival; Ki 67 antigen; Melanoma; Prognosis; Recurrence

Indexed keywords

KI 67 ANTIGEN; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE OVEREXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT CANCER; RISK ASSESSMENT; TUMOR GROWTH;

DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; L-LACTATE DEHYDROGENASE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 79959390407     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000328518     Document Type: Article

References (44)

1. Gimotty PA, Guerry D, Ming ME, Elenitsas R, Xu X, Czerniecki B, Spitz F, Schuchter L, Elder D: Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol 2004; 22: 3668-3676. (Pubitemid 41095205)
2. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
3. Balch CM, Soong SJ, Smith T, Ross MI, Urist MM, Karakousis CP, Temple WJ, Mihm MC, Barnhill RL, Jewell WR, Wanebo HJ, Desmond R, Investigators from the Intergroup Melanoma Surgical Trial: Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001; 8: 101-108. (Pubitemid 32199405)
4. Francken AB, Accortt NA, Shaw HM, Wiener M, Soong SJ, Hoekstra HJ, Thompson JF: Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol 2008; 15: 1476-1484.
5. Dalal KM, Patel A, Brady MS, Jaques DP, Coit DG: Patterns of first-recurrence and post-recurrence survival in patients with primary cutaneous melanoma after sentinel lymph node biopsy. Ann Surg Oncol 2007; 14: 1934-1942. (Pubitemid 46870940)
6. Cohn-Cedermark G, Mansson-Brahme E, Rutqvist LE, Larsson O, Singnomklao T, Ringborg U: Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma. Acta Oncol 1999; 38: 549-557. (Pubitemid 29333734)
7. Soong SJ, Harrison RA, McCarthy WH, Urist MM, Balch CM: Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol 1998; 67: 228-233. (Pubitemid 28196912)
8. Fusi S, Ariyan S, Sternlicht A: Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast Reconstr Surg 1993; 91: 94-98. (Pubitemid 23101858)
9. Crowley NJ, Seigler HF: Relationship between disease-free interval and survival in patients with recurrent melanoma. Arch Surg 1992; 127: 1303-1308.
10. Reintgen DS, Cox C, Slingluff CL Jr, Seigler HF: Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg 1992; 28: 45-49.
11. Markowitz JS, Cosimi LA, Carey RW, Kang S, Padyk C, Sober AJ, Cosimi AB: Prognosis after initial recurrence of cutaneous melanoma. Arch Surg 1991; 126: 703-708.
12. Hoyt DJ, Fisher SR: Survival following recurrent malignant melanoma of the head and neck. Laryngoscope 1989; 99: 586-589. (Pubitemid 19155261)
13. Shaw HM, Beattie CW, McCarthy WH, Milton GW: Late relapse from cutaneous stage I malignant melanoma. Arch Surg 1985; 120: 1155-1159. (Pubitemid 16229691)
14. Karakousis CP, Temple DF, Moore R, Ambrus JL: Prognostic parameters in recurrent malignant melanoma. Cancer 1983; 52: 575-579. (Pubitemid 13073490)
15. Bogunovic D, O'Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, Adams S, Darvishian F, Berman R, Shapiro R, Pavlick AC, Lonardi S, Zavadil J, Osman I, Bhardwaj N: Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA 2009; 106: 20429-20434.
16. Reintgen DS, Vollmer R, Tso CY, Seigler HF: Prognosis for recurrent stage I malignant melanoma. Arch Surg 1987; 122: 1338-1342. (Pubitemid 18021293)
17. Gerdes J, Schwab U, Lemke H, Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13-20. (Pubitemid 13179545)
18. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ: Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 966-978.
19. Keshgegian AA, Cnaan A: Proliferation markers in breast carcinoma: mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol 1995; 104: 42-49.
20. Gaglia P, Bernardi A, Venesio T, Caldarola B, Lauro D, Cappa AP, Calderini P, Liscia DS: Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: its prognostic value on short-term recurrences. Eur J Cancer 1993; 29A:1509-1513. (Pubitemid 23251787)
21. Railo M, Nordling S, von Boguslawsky K, Leivonen M, Kyllonen L, von Smitten K: Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer 1993; 68: 579-583. (Pubitemid 23258465)
22. Mucci NR, Rubin MA, Strawderman MS, Montie JE, Smith DC, Pienta KJ: Expression of nuclear antigen Ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens. J Natl Cancer Inst 2000; 92: 1941-1942. (Pubitemid 32036925)
23. Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW: Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1996; 156: 1064-1068. (Pubitemid 26269830)
24. Wich LG, Hamilton HK, Shapiro RL, Pavlick A, Berman RS, Polsky D, Goldberg JD, Hernando E, Manga P, Krogsgaard M, Kamino H, Darvishian F, Lee P, Orlow SJ, Ostrer H, Bhardwaj N, Osman I: Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. Am J Transl Res 2009; 1: 35-43.
25. Spyratos F, Ferrero-Pous M, Trassard M, Hacene K, Phillips E, Tubiana-Hulin M, Le Doussal V: Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer 2002; 94: 2151-2159. (Pubitemid 34411971)
26. MacFarlane R, Speers C, Masoudi H, Chia S: Molecular changes in the primary breast cancer versus the relapsed/metastatic lesion from a large population based database and tissue microarray series (abstract). J Clin Oncol 2008; 26: 15s.
27. Broglio K, Moulder SL, Hsu L, Kau S, Pusztai L, Symmans WF, Hortobagyi GN, Gonzalez-Angulo AM, Liedtke C: Prognostic impact of discordance/concordance of triple-receptor expression between primary tumor and metastasis in patients with metastatic breast cancer (abstract). J Clin Oncol 2008; 26: 15s.
28. Hernberg M, Turunen JP, von Boguslawsky K, Muhonen T, Pyrhönen S: Prognostic value of biomarkers in malignant melanoma. Melanoma Res 1998; 8: 283-291. (Pubitemid 28313768)
29. Vlaykova T, Talve L, Hahka-Kemppinen M, Hernberg M, Muhonen T, Franssila K, Collan Y, Pyrhönen S: MIB-1 immunoreactivity correlates with blood vessel density and survival in disseminated malignant melanoma. Oncology 1999; 57: 242-252. (Pubitemid 29481699)
30. Gimotty PA, Van Belle P, Elder DE, Murry T, Montone KT, Xu X, Hotz S, Raines S, Ming ME, Wahl P, Guerry D: Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol 2005; 23: 8048-8056. (Pubitemid 46657407)
31. Ladstein RG, Bachmann IM, Straume O, Akslen LA: Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer 2010; 10: 140.
32. Petrowsky H, Sturm I, Graubitz O, Kooby DA, Staib-Sebler E, Gog C, Kohne CH, Hillebrand T, Daniel PT, Fong Y, Lorenz M: Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. Eur J Surg Oncol 2001; 27: 80-87. (Pubitemid 32229699)
33. Smith DL, Soria JC, Morat L, Yang Q, Sabatier L, Liu DD, Nemr RA, Rashid A, Vauthey JN: Human telomerase reverse transcriptase (hTERT) and Ki-67 are better predictors of survival than established clinical indicators in patients undergoing curative hepatic resection for colorectal metastases. Ann Surg Oncol 2004; 11: 45-51.
34. Lee CC, Faries MB, Wanek LA, Morton DL: Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol 2009; 27: 3489-3495.
35. Lee CC, Faries MB, Wanek LA, Morton DL: Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol 2008; 26: 535-541. (Pubitemid 351264345)
36. Anbari KK, Schuchter LM, Bucky LP, Mick R, Synnestvedt M, Guerry D 4th, Hamilton R, Halpern AC: Melanoma of unknown primary site: presentation, treatment, and prognosis-a single institution study. Cancer 1997; 79: 1816-1821. (Pubitemid 27176366)
37. Schlagenhauff B, Stroebel W, Ellwanger U, Meier F, Zimmermann C, Breuninger H, Rassner G, Garbe C: Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations. Cancer 1997; 80: 60-65. (Pubitemid 27270920)
38. Nambisan RN, Alexiou G, Reese PA, Karakousis CP: Early metastatic patterns and survival in malignant melanoma. J Surg Oncol 1987; 34: 248-252. (Pubitemid 17061918)
39. Papadopoulos I, Rudolph P, Weichert-Jacobsen K, Thiemann O, Papadopoulou D: Prognostic indicators for response to therapy and survival in patients with metastatic renal cell cancer treated with interferon alpha-2 beta and vinblastine. Urology 1996; 48: 373-378. (Pubitemid 26317475)
40. Soengas MS, Lowe SW: Apoptosis and melanoma chemoresistance. Oncogene 2003; 22: 3138-3151. (Pubitemid 36713766)
41. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T, Herlyn M: A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010; 141: 583-594.
42. Becker JC, Kirkwood JM, Agarwala SS, Dummer R, Schrama D, Hauschild A: Molecularly targeted therapy for melanoma: current reality and future options. Cancer 2006; 107: 2317-2327. (Pubitemid 44748514)
43. Lorigan P, Eisen T, Hauschild A: Systemic therapy for metastatic malignant melanoma-from deeply disappointing to bright future Exp Dermatol 2008; 17: 383-394. (Pubitemid 351513952)
44. Dai DL, Martinka M, Bush JA, Li G: Reduced Apaf-1 expression in human cutaneous melanomas. Br J Cancer 2004; 91: 1089-1095. (Pubitemid 39336247)